Ozonoterapia y cáncer: mito o realidad / Ozone Therapy and Cancer: Myth or Reality

Introducción: El uso clínico de la ozonoterapia se incrementa cada día. Abarca disímiles especialidades médicas como la oncología. En Cuba las investigaciones que evalúan el empleo de la ozonoterapia en pacientes con cáncer son escasas, se precisan estudios científicos que demuestren su eficacia clínica. Objetivo: Explicar los mecanismos farmacológicos y bioquímicos de la ozonoterapia y su uso en el cáncer como terapia complementaria. Métodos: Se consultaron bases de datos disponibles a través de la red de Infomed. Se utilizaron como palabras clave: cáncer, ozonoterapia y estrés oxidativo. Se seleccionaron artículos originales y de revisión sistemáticos de los últimos diez años que evaluaron la utilización de la ozonoterapia en el tratamiento del cáncer. Resultados: El cáncer es per se una enfermedad inductora de estrés oxidativo. La ozonoterapia respalda su utilización como una terapia adyuvante mediante el preacondicionamiento oxidativo que estimula los sistemas antioxidantes de la célula contra la acción de los radicales libres. Así, se logra neutralizar la acción nociva del estrés oxidativo. El ozono incrementa la eficacia de la radio - quimioterapia y ayuda a reducir los efectos secundarios de estos tratamientos al activar los sistemas antioxidantes de la célula. La ozonoterapia se caracteriza por la simplicidad de su aplicación, bajos costos, alta efectividad y prácticamente ausencia de efectos colaterales en comparación con otros tratamientos adyuvantes. Conclusiones: El uso de la ozonoterapia en oncología como una terapia adyuvante representó un recurso terapéutico de gran valor dado por su perfil de efectividad y seguridad. Su uso podría extenderse para disminuir los efectos secundarios y mejorar la calidad de vida de los pacientes(AU)

Introduction: The clinical use of ozone therapy is increasing every day worldwide and it covers different medical specialties, including oncology. However, in Cuba, the investigations that evaluate the use of ozone therapy in cancer patients are scarce, so scientific studies are needed to demonstrate its clinical efficacy. Objective: To explain the pharmacological and biochemical mechanisms of ozone therapy and its use in cancer as a complementary therapy. Methods: Databases available through Infomed Network were consulted. Key words used were cancer, ozone therapy and oxidative stress. Original and systematic review articles from the last ten years that evaluated the use of ozone therapy in the treatment of cancer were selected. Results: Cancer is, as such, a disease that induces oxidative stress. Ozone therapy supports its use as an adjuvant therapy through oxidative pre-conditioning that stimulates the cell's antioxidant systems against the action of free radicals. Thus, it is possible to neutralize the harmful action of oxidative stress. Ozone increases the efficacy of radio-chemotherapy and helps reducing the side effects of these treatments by activating the cell's antioxidant systems. Ozone therapy is characterized by the simplicity of its application, low costs, high effectiveness and with practically no side effects, compared to other adjuvant treatments. Conclusions: The use of ozone therapy in oncology as an adjuvant therapy represented a therapeutic resource of great value given its effectiveness and safety profile. Its use could be extended to improve tissue oxygenation and thus enhance the efficacy of radiochemotherapy, reducing side effects and improving the patients's quality of life(AU)

Uso de PET-CT en el delineado de volumen en la planificación del tratamiento con radiación / Use of PET-CT in the one delineated of volume in the planning of the one radiant treatment

El tratamiento con radioterapia, consiste en irradiar de forma homogénea el tumor, evitando irradiar los órganos cercanos. El desarrollo de la tecnología en el campo de la medicina, ha permitido que se cumpla este principio, con buenos resultados de respuesta objetiva, que se traduce en el control de la enfermedad de los pacientes con cáncer. La Tomografía axial computarizada por emisión de positrones (PET-CT) consigue una mayor precisión en el delineado del volumen blanco o tumoral. El propósito de este estudio fue analizar la influencia del uso del PET-CT en el delineado de volúmenes a tratar en la planificación del tratamiento con radiaciones.Se diseñó un estudio piloto con dos pacientes preparados para radioterapia por neoplasias malignas, a los cuáles se les realizó un TAC simple y un PET-CT y observadores independientes realizaron la delimitación del tumor. Se examinó la consistencia entre los observadores y las mediciones en las imágenes.El uso del PET-CT favoreció la delimitación del volumen a irradiar lo que disminuye el riesgo para los órganos vecinos.

The treatment with radiotherapy consists on irradiating in a homogeneous way the tumor, avoiding to irradiate the near organs. The development of the technology in the field of the medicine, it has allowed that this principle is completed, with good results of objective answer what allows the control of the illness of the patients with cancer. The computerized axial tomography by positrons emission (PET-CT) it gets a bigger precision in the one delineated of the white volume or tumoral. The purpose of this study was to analyze the influence of the use of the PET-CT in the one delineated of volumes to try in the planning of the treatment with radiations.A study pilot was designed with two prepared patients for radiotherapy for malignant diseases, to those which they were carried out a simple TAC and a PET-CT and independent observers carried out the delimitation of the tumor. The consistency was examined between the observers and the mensuration in the images.The use of the PET-CT favors the delimitation of the volume to irradiate what diminishes the risk for the neighboring organs.

Radioprotective natural products as alternative complements in oncological radiotherapy / Productos naturales radioprotectores como complementos alternativos en la radioterapia oncológica

Humans when exposed to harmful ionising radiations suffer from various pathophysiological disorders including cancer. Radiotherapy is a treatment where these cancerous cells within a tumor aretargeted and killed by means of high energy waves. This therapy is very expensive and involves highly sophisticated instruments. In addition to this, most synthetic radioprotectors including Amifostine have been found to possess toxicity. This led researchers to develop a novel, economically viable, and efficient therapeutic alternative to radiation therapy. The last two decades have observed a major shift towards investigating natural products as radioprotectors, as these are immensely effective in terms of their potential bioequivalence relative to many of the established synthetic compounds available. Taking into account the limitations of radiation therapy, an approach 'Integrative Oncology' that involves a combination of both traditional and conventional medical treatment are used nowadays to treat patients suffering from cancer and associated mental and psychological disorders.

Los seres humanos, cuando se exponen a radiaciones ionizantes nocivas, sufren diversos trastornos fisiopatológicos, incluido el cáncer. La radioterapia es un tratamiento en el que estas células cancerosas dentro de un tumor son atacadas y destruidas por medio de ondas de alta energía. Esta terapia es muy cara e implica instrumentos muy sofisticados. Además de esto, se ha descubierto que la mayoría de los radioprotectores sintéticos, incluida la amifostina, poseen toxicidad. Esto llevó a los investigadores a desarrollar una novedosa, económicamente viable y eficiente alternativa terapéutica a la radioterapia. En las dos últimas décadas se ha observado un cambio importante hacia la investigación de productos naturales como radioprotectores, ya que son inmensamente eficaces en términos de su potencial bioequivalencia en relación con muchos de los compuestos sintéticos establecidos disponibles. Teniendo en cuenta las limitaciones de la radioterapia, hoy en día se utiliza un enfoque de "Oncología Integrativa" que implica una combinación de tratamiento médico tradicional y convencional para tratar a pacientes que padecen cáncer y trastornos mentales y psicológicos asociados.

A New Generation of Radiotherapy Technology-Flash Radiotherapy / 中国医疗器械杂志

Flash radiotherapy is a kind of radiotherapy method using ultra-high dose rate radiation. Compared with the traditional dose rate radiotherapy, it has unique radiobiological advantages. In this paper, the principle of flash radiotherapy, the process and results of biological experiments are summarized. At the same time, the advantages and challenges of flash radiotherapy are analyzed, and the future clinical application is prospected.

The Impact of Radiotherapy in the in Vitro Remineralization of Demineralized Enamel

Objective: To evaluate the impact of radiotherapy on enamel around restorations of glass ionomer cement (GIC) and fluoride tooth paste (FTP). Material and Methods: Eighty enamel blocks were made and randomly distributed into two groups, according to the fluoride therapy, non-fluoride tooth paste (NFTP) and FTP (n=40) and in subgroups in conformity with radiation dose (0, 10, 30 and 60 Gy). Roughness and microhardness enamel analyses were conducted before radiotherapy. Enamel cavities were made and restored with two GIC (Ketac Molar Easy Mix or Vitremer). Enamel blocks were submitted to 10, 30 and 60 Gy. Then, artificial enamel caries lesions were created by a pH-cycling procedure and FTP or NFTP were used as treatment. The restored enamel blocks were submitted to final roughness and microhardness analyses. Roughness increase (ΔR) and hardness loss (ΔH) values of enamel were submitted to ANOVA and Tukey test (p=0.05). Results: The irradiated enamel group showed statistically higher ΔR (0.44 ±0.2) and ΔH (99.26±7.0) values compared to non-irradiated group (ΔR = 0.051±0.02; ΔH=66.16±12.7) when a resin-modified GIC and NFTP were used. Conclusion: Higher radiation dose increased dissolution of bovine enamel. The use of GIC associated with FTP decreased roughness and increased enamel hardness after radiotherapy.

Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning

The efficacy and toxicity of radionuclide therapy are believed to be directly related to the radiation doses received by target tissues; however, nuclear medicine therapy continues to be based primarily on the administration of empirical activities to patients and less frequently on the use of internal dosimetry for individual therapeutic planning. This review aimed to critically describe the techniques and clinical evidence of dosimetry as a tool for therapeutic planning and the main limitations to its implementation in clinical practice. The present article is a nonsystematic review of voxel-based dosimetry. Clinical evidence pointing to a correlation between the radiation dose and therapeutic response in various diseases, such as thyroid carcinoma, neuroendocrine tumors and prostate cancer, is reviewed. Its limitations include technical aspects related to image acquisition and processing and the lack of randomized clinical trials demonstrating the impact of dosimetry on patient therapy. A more widespread use of dosimetry in therapeutic planning involves the development of user-friendly dosimetric protocols and confirmation that dose estimation implies good efficacy and low treatment-related toxicity.

Nimotuzumab y radioterapia en el tratamiento de tumores del tallo cerebral en niños y adolescentes / Nimotuzumab and radiotherapy in the treatment of brainstem tumors in children and adolescents

Introducción: Los tumores localizados en el tallo cerebral en los niños y adolescentes conllevan un mal pronóstico, especialmente aquellos infiltrantes y difusos. Con el tratamiento de radioterapia apenas llegan a más de 15 por ciento de supervivencia y no mejora la cifra con quimioterapia agregada. Objetivos: Estimar el efecto de la asociación del tratamiento radiante con el anticuerpo monoclonal Nimotuzumab en la supervivencia de niños y adolescentes con tumores del tallo cerebral. Método: Estudio clínico no aleatorizado, analítico, longitudinal y prospectivo. Se estudió una serie de 46 pacientes entre 2 y 18 años de edad que padecían de tumores del tallo cerebral, infiltrantes y difusos, desde enero de 2008 y en seguimiento hasta marzo de 2018. Todos se trataron con radioterapia, con dosis entre 54 y 59,8 cGrey, dosis diaria de 1,8 cGrey, y se irradiaban de lunes a viernes. Mientras duró el tratamiento radiante recibieron Nimotuzumab, en la dosis de 150 mg/m2 de superficie corporal, luego semanal con 8 dosis, y finalmente mensual durante uno o dos años. Resultados: Se alcanzó en la serie una supervivencia media de 18,4 meses, y una esperada de 42,9 por ciento a 2 años y 35,5 por ciento a 5 años, estabilizada hasta los 10 años. Conclusiones: La combinación de radioterapia y el anticuerpo monoclonal Nimotuzumab incrementa la supervivencia en niños y adolescentes con tumores del tallo cerebral y es bien tolerada, aun en periodos prolongados, e incluso en casos de recidiva(AU)

Introduction: Tumors localized in the brainstem of children and adolescents entail a bad prognosis, especially those that are intrinsic and diffuse. With radiotherapy treatment, patients barely get a 15 percent of survival, and the numbers don't improve with added chemotherapy. Objectives: To estimate the effect of the association of radiotherapy treatment with Nimotuzumab monoclonal antibody in the survival of children and adolescents with brainstem tumors. . Method: Non randomized, analytical, longitudinal and prospective clinical study that was authorized by the National Regulatory Authority. There was studied a group of 46 patients aged from 2 to 18 years that suffered from intrinsic and diffuse brainstem tumors, from January 2008 (and in follow up) to March 2018. All the patients were treated with radiotherapy, with doses among 54 and 59,8 Grey, daily doses of 1,8 Grey, and from Monday to Friday. While they were under radiotherapy treatment, they get Nimotuzumab, in doses of 150 mg/m2 of corporal surface; then weekly doses of 8 shots; and finally, monthly doses during one or two years. Results: In this group there was a survival mean of 18, 4 months, and an expected survival of 42, 9 percent for 2 years and 35, 5 percent for 5 years that can be stabilized to 10 years. Conclusions: Combination of radiotherapy and Nimotuzumab monoclal antibody can increase the survival from brainstem tumors in children and adolescents(AU)

Fadiga: Um sintoma complexo e seu impacto no câncer e na Insuficiência cardíaca / Fatigue: a complex symptom and its impact on cancer heart failure

Nas doenças crônicas, como câncer e insuficiência cardíaca (IC), a fadiga é um sintoma comum e complexo do ponto de vista etiológico e fisiopatológico, portanto, um tema de relevância na recente área da cardio-oncologia. A fadiga é prevalente em 80-90% dos pacientes oncológicos tratados com quimioterapia e/ou radioterapia e acomete cerca de 50-96% dos indivíduos com IC. A toxicidade atribuída aos quimioterápicos pode determinar o grau de fadiga do paciente e até predizer sua sobrevida. Nas últimas décadas, o avanço das terapias antineoplásicas impactaram substancialmente a sobrevida dos pacientes com câncer, e os riscos dos efeitos lesivos destas terapias ao sistema cardiovascular têm sido cada vez mais descritos. Portanto, a cooperação entre oncologistas e cardiologistas levou ao surgimento da cardio-oncologia e do novo conceito de cardiovigilância. A cardiotoxicidade é uma das complicações clínicas no tratamento do câncer, apresentando como manifestação típica a disfunção sistólica ventricular esquerda. Novas estratégias diagnósticas e terapêuticas têm sido empregadas na cardiovigilância em pacientes com câncer. A fadiga nestes pacientes vem sendo estudada criteriosamente com um olhar multidisciplinar e com o desenvolvimento de escalas visuais para melhor quantificar e correlacionar o seu real impacto na qualidade de vida e sobrevida destes indivíduos. O Pictograma de Fadiga e Escala de Fadiga de Piper são ferramentas cada vez mais utilizadas na pesquisa e na prática clínica. Os mecanismos envolvidos na fadiga, do ponto de vista conceitual, podem ser de origem central (sistema nervoso central) ou periférica (musculoesquelética), ambos os quais podem estar presentes no paciente com câncer. A presente revisão objetiva discutir os novos conceitos na avaliação da fadiga em pacientes oncológicos. Esses conceitos são fundamentais aos profissionais que atuam na emergente área da cardio-oncologia

Avaliação da influência da radioterapia nas reconstruções de mama com TRAM / Evaluation of the effects of radiotherapy on breast reconstruction with a transverse rectus abdominis myocutaneous flap

Introdução: A radiação influencia negativamente os resultados das reconstruções de mama que utilizam implantes. No entanto, os efeitos da radiação sobre as reconstruções de mama apenas com tecidos autólogos ainda não está clara. O objetivo do trabalho é avaliar as complicações pós-operatórias de pacientes submetidas à reconstrução de mama com retalho do músculo reto abdominal (TRAM) imediato e tardio e correlacionar estatisticamente essas complicações com a presença ou não da radioterapia (RT). Métodos: Levantamento retrospectivo de prontuários de pacientes submetidas à reconstrução mamária, das quais 126 pacientes realizaram reconstrução mamária com TRAM no período de 2004 a 2011. Foram analisadas a presença ou não de RT e as complicações pós-operatórias nas reconstruções imediatas e tardias. As pacientes foram divididas em 3 grupos: 1) sem RT (somente TRAM), 2) (TRAM→RT), 3) (RT→TRAM). Para cada grupo foi avaliada a presença e ausência de complicações menores e maiores e aplicados testes estatísticos. Resultados: Os grupos estudados foram considerados homogêneos quanto a idade e índice de massa corporal. Houve maior incidência de complicações maiores nos grupos com RT após o TRAM (29,6%) em relação aos demais grupos: sem RT (23,4%) e RT antes do TRAM (5,6%). Entretanto, a diferença entre os grupos não se mostra estatisticamente significativa. Para as Complicações Menores, também não há evidências de diferenças estatisticamente significativas entre os grupos. Conclusão: Nesse estudo a radioterapia adjuvante não se mostrou como fator potencializador de complicações nas pacientes submetidas à reconstrução imediata com TRAM pós-mastectomia.

Introduction: Radiation negatively influences the results of breast reconstruction using implants. However, the effects of radiation on breast reconstruction with autologous tissue is still unclear. The objective of this study was to evaluate the postoperative complications in patients who underwent immediate and late breast reconstruction with a transverse rectus abdominis myocutaneous (TRAM) flap and statistically correlate these complications with the use of radiotherapy (RT). Methods: A retrospective survey of the medical records of patients who underwent breast reconstruction was conducted. Of the patients, 126 underwent breast reconstruction with a TRAM flap between 2004 and 2011. The presence or absence of RT and postoperative complications in the immediate and late reconstructions was assessed. The patients were divided into 3 groups as follows: 1) without RT (TRAM alone group), 2) TRAM→RT group, and 3) RT→TRAM group. The patients in each group were evaluated for the presence and absence of minor and major complications, and results were statistically analyzed. Results: The groups were considered homogenous for age and body mass index. The incidence of major complications was higher in the groups with RT after TRAM (29.6%) than in the other groups, namely the groups without RT (23.4%) and with RT before TRAM flap reconstruction (5.6%). However, the differences among the groups were not statistically significant. No evidence of statistically significant differences in minor complications were found among the groups. Conclusion: In this study, adjuvant RT was not a potentiating factor of complications in the patients who underwent immediate reconstruction with a TRAM flap after mastectomy.

Respuesta al tratamiento neoadyuvante con capecitabine y radioterapia en el cáncer de recto inferior localmente avanzado / Response to neoadjuvant treatment with capecitabine and radiotherapy in locally advanced lower rectal cancer

Introducción: La importancia del tratamiento neoadyuvante con quimio y radioterapia en el manejo de los tumores de recto extraperitoneal localmente avanzado ha quedado claramente demostrada. La droga que ha sido históricamente más utilizada para este fin fue el 5-Fluorouracilo (5-FU). Una nueva molécula de administración por vía oral, la prodroga capecitabine, ha reemplazado al 5-FU en el tratamiento neoadyuvante en los últimos tiempos, con mejores resultados y mayor comodidad. Objetivo: Valorar la eficacia, toxicidad y complicaciones del tratamiento neoadyuvante con capecitabine más radioterapia en el tratamiento del cáncer de recto extraperitoneal localmente avanzado. Diseño: Estudio observacional, descriptivo, retrospectivo. Población y Métodos: Se incluyeron 33 pacientes (66% de sexo masculino) con tumores de recto extraperitoneal localmente avanzado (cT3/cT4 o cN+) con indicación de neoadyuvancia. La dosis de radioterapia fue de 45 Gy más un boost de 5,04 Gy administradas en 25 sesiones durante un período de 5 semanas. La dosis de capecitabine fue de 850 mg/m2, dos veces al día durante los días en que se administraba la radioterapia. Se reevaluó a los pacientes entre la 8º y 10º semana. Aquellos pacientes con respuesta clínica completa (RCC) se les ofreció ingresar al protocolo de Watch & Wait, mientras que aquellos pacientes con respuesta clínica incompleta o nula se les indicó la resección quirúrgica entre las 10-12 semanas posttratamiento neoadyuvante. Resultados: 10 pacientes (30,3%) tuvieron respuesta clínica completa (RCC). De estos, 7 entraron a protocolo Watch & Wait. Se operaron 26 pacientes, luego de un promedio de 11,71 semanas posteriores a la neoadyuvancia, siguiendo en todos los casos la técnica de excisión total del mesorrecto. Se observó un 19,3% de RPC y un downstaging del 57,69%. A dieciséis pacientes (61,53%) se les efectuó una resección anterior ultrabaja con ostomía de protección. Nueve pacientes fueron sometidos a una amputación abdominoperineal (34,61%) y una paciente recibió una operación de Hartmann (3,84%). El principal efecto adverso fue la diarrea grado I en el 36% de los casos, seguida por la dermatitis grado I en el 33%. Tuvimos dos dehiscencias anastomóticas que se resolvieron sin reintervención. Conclusiones: El tratamiento neoadyuvante con capecitabine es una opción segura, con alta tasa de respuesta clínica y patológica completa, con escasa toxicidad y complicaciones, y el beneficio de la comodidad de su administración por vía oral. (AU)

Background: The importance of neoadjuvant chemotherapy and radiation therapy in the management of extraperitoneal rectal tumors locally advanced has been clearly demonstrated. The drug has been historically used for this purpose was 5-fluorouracil (5-FU). A new molecule oral administration, the prodrug capecitabine, has replaced the 5-FU in the neoadjuvant treatment in recent times, with better results and greater comfort. Objective: To evaluate the efficacy, toxicity and complications of neoadjuvant capecitabine plus radiation therapy in the treatment of locally advanced rectal cancer extraperitoneal. Design: Observational, descriptive, retrospective study. Population and Methods: 33 patients (66% male) with extraperitoneal rectal tumors locally advanced (cT3 / cT4 or cN +) with indication of neoadjuvant were included. Radiation dose was 45 Gy plus a boost of 5.04 Gy administered in 25 sessions over a period of 5 weeks. Capecitabine dose was 850 mg / m2 twice daily on days that radiotherapy was administered. It was reevaluated patients between the 8th and 10th week. Patients with clinical complete response (CCR) were offered to enter the protocol Watch & Wait, while patients with incomplete or no clinical response were instructed surgical resection neoadjuvant between 10-12 weeks post-treatment. Results: 10 patients (30.3%) had clinical complete response (CCR). Of these, seven entered Watch & Wait protocol. 26 patients were operated after a mean time of 11,71 weeks (range 10-15), in all cases following the total mesorectal excision technique. 19.3% of RPC and downstaging of 57.69% was observed. Sixteen patients (61.53%) were made ultra-low anterior resection with protective stoma. Nine patients underwent an AP amputation (34.61%) and one patient received a Hartmann operation(3.84%). The main side effect was diarrhea grade I in 36% of cases, followed by the degree I dermatitis in 33%. We had two anastomotic dehiscences which resolved without reoperation. Conclusions: Neoadjuvant capecitabine therapy is a safe choice, with high rate of complete clinical and pathological response with low toxicity and complications, and the benefit from the comfort of oral administration. (AU)

Carcinoma epidermoide de la lengua: presentación de un caso / Epidermoid carcinoma of the tongue: report of a case

El carcinoma epidermoide es el cáncer bucal más frecuente que representamás de 90% de todos los tipos de cáncer de la cavidad oral. Se presenta el caso de masculino de 41 años de edad con un carcinoma epidermoide de rápida evolución a nivel de la lengua. Se observó una estomatosis localizada en el borde izquierdo de la lengua caracterizada por una neoformación de bordes elevados indurados, centro ulcerado, de 2 cm de diámetro y friable. Se detectaron adenomegalias del lado izquierdo de 2 cm. El paciente refería dolor a nivel del cuello y a niveldel oído izquierdo. Fumaba hasta dos cajetillas de cigarros al día. El estudio histopatológico reveló un carcinoma epidermoide ulcerado, invasor con áreas moderadamente poco diferenciadas. Se inició tratamientocon radioterapia 25 sesiones y quimioterapia con cisplatino. Se determinó mala tolerancia y respuesta al tratamiento establecido, por lo que éste se suspendió y se optó por tratamientos paliativos. La evolución del paciente fue tórpida y falleció a los 10 meses del diagnóstico. Las neoplasias de la cavidad oral son relativamente poco frecuentes, pero la letalidad alcanza hasta 78 por ciento entre las neoplasias de las vías aerodigestivas superiores y se diagnostican en etapas avanzadasen 65 por ciento de los casos. La prevención es fundamental, sobre todo la supresión del tabaquismo.

Epidermoid carcinoma is the most frequent oral cancer (90% of alloral cancer). We present the case of a 41-year-old man with oralcancer on the tongue. The lesion was localized on the left side of thetongue and was characterized by an ulcerated tumor with induratedborders, 2 cm of diameter. Lymph node metastasis was detected onthe neck. The patient had left ear pain and also a pain in the neck.He smoked two packs of cigarettes per day. The histopathologic studyrevealed an epidermoid carcinoma with poor and well-diff erentiatedareas. Radiotherapy and chemotherapy with cisplatin on were started.The patient did not tolerate and had a poor response, so the treatmentwas suspended. The patient died 10 months after the diagnosis. Oralcarcinoma is not frequent but the mortality is high, 78%, between thecarcinomas of the aerodigestive tract and frequently it is diagnosedwhen in advanced stages in 65% of the cases. The most important arethe prevention, mostly, tobacco consumption.

Reabilitação maxilar após radioterapia utilizando implante unitário e prótese obturadora tipo overdenture: acompanhamento clínico de um ano / Maxillary rehabilitation after radiotherapy using a single-tooth dental implant and the obturator-type overdenture: one-year clinical follow-up

Este caso clínico relata o uso de uma prótese obturadora tipo overdenture para compensar a deficiência estética em um paciente previamente irradiado. Um indivíduo do sexo masculino, 73 anos de idade, que possuía uma prótese sobre três implantes dentários foi acometido de câncer no seio maxilar e assoalho da órbita. Seis doses de cisplatina e 35 sessões de radioterapia (dose diária 1,8 Gy) foram executadas. Após a maxilectomia, apenas um implante restou na região anterior. O tratamento consistiu de uma prótese obturadora tipo overdenture com encaixe tipo Equator. O paciente retornou um ano depois, sem alterações estéticas e com nível de satisfação melhorado. Entretanto, o anel borrachoide do encaixe foi trocado. Reabilitações implantossuportadas e mucorretidas que recebem carregamento tardio pode melhorar o prognóstico de implantes dentais em pacientes irradiados. Este cuidado mostra que este cenário ainda requer maior atenção da comunidade científica, na busca por meios de prevenir e minimizar os danos causados pela radioterapia, por inovações tecnológicas e protocolos regenerativos que potencializem a osseointegração. Com isso, a Odontologia poderá contribuir ainda mais com a melhora da qualidade de vida de pacientes, devolvendo satisfação pessoal e autoestima.

This case describes the use of an obturator-type overdenture prosthesis to compensate for the aesthetic defi ciency in a previously irradiated patient. A 73 years-old male, who had a prosthesis on three dental implants was diagnosed with cancer in the maxillary sinus and orbital floor. Six doses of cisplatin and 35 radiotherapy sessions (daily doses of 1.8 Gy) were performed. After maxillectomy, only one implant survived in the anterior region. The treatment consisted of an obturator overdenture with the Equator attachment. The patient returned one year later without cosmetic changes and demonstrated an enhanced satisfaction level. However, the o-ring rubber was replaced. Implant-supported, mucosa-retained restorations receiving delayed loading can improve the prognosis of dental implants in irradiated patients. Also, this scenario still requires more attention from the scientific community seeking for new ways to prevent and minimize damages caused by radiation, technological innovations, and regenerative protocols that enhance osseointegration. Thus, dentistry can further contribute to improving the quality of life of patients, returning their personal satisfaction and self-esteem.

Empleo de la radioterapia en el tratamiento a los tumores del sistema nervioso central en niños y adolescentes / Use of radiotherapy in treating central nervous system tumors of children and adolescents

INTRODUCCIÓN: los tumores del sistema nervioso central en los niños y adolescentes constituyen en Cuba la tercera localización en orden de frecuencia de todas las neoplasias; el tratamiento consiste en cirugía, seguida de la irradiación en la mayoría de los casos, y en algunos tipos histológicos, se añade la quimioterapia, o los anticuerpos monoclonales. OBJETIVO: valorar el empleo de la radioterapia en el tratamiento a los tumores del sistema nervioso central en niños y adolescentes. MÉTODOS: se trata de una serie de 98 niños y adolescentes entre 3 y 18 años de edad que fueron irradiados en el Instituto Nacional de Oncología y Radiobiología por padecer: 32 casos tumores del tallo cerebral (32,6 %), 19 meduloblastomas (19,4 %), 11 astrocitomas grado I-II (11,2 %), 9 astrocitomas III-IV y glioblastomas multiformes (gliomas de alto grado, 9,2 %), 6 craneofaringiomas (6,1 %), 6 tumores primitivos neuroectodérmicos (6,1 %), 5 oligodendrogliomas (5,1 %), 4 ependimomas (4,1 %), 3 germinomas (3,1 %), 2 pineoblastomas (2,1 %) y 1 caso de gliomatosis (1 %). Los pacientes fueron irradiados con aceleradores lineales, máscaras termoplásticas de inmovilización, planificación en 3D, conformada, o intensidad modulada, controles dosimétricos y de imágenes; en niños pequeños, se utilizó anestesia. RESULTADOS: 47 pacientes se encuentran vivos (47,9 %), con una tasa de supervivencia de 5 años de 50,2 %, y una mediana de 5,34 años. CONCLUSIONES: la radioterapia resulta ser un arma terapéutica eficaz para tumores del sistema nervioso central en niños y adolescentes.

INTRODUCTION: central nervous system tumors of children and adolescents are the most frequent location of neoplasias in Cuba, their treatment involves surgery followed by radiation in most cases, and chemotherapy or monoclonal antibodies in some histological types of tumors. OBJECTIVE: to evaluate the use of radiotherapy in treating central nervous system tumors of children and adolescents. METHODS: a series of 98 children and adolescents aged 3 to 18 years were treated with radiation at the National Institute of Oncology and Radiobiology including 32 brainstem tumors(32.6 %), 19 medulloblastomas (19.4 %), 11 grade I- II astrocytomas (11,2 %), 9 grade III-IV astrocytomas and multiform glioblastomas (high grade gliomas, 9.2 %), 6 craniopharyngiomas (6.1 %), 6 primitive neuroectodermal tumors (6.1 %), 5 oligodendrogliomas (5.1 %), 4 ependymonas (4.1 %), 3 germinomas (3.1 %), 2 pineoblastomas (2.1 %) and one case of gliomatosis (1 %). The patients were irradiated with linear accelerators, thermoplastic masks of immobilization, conformal 3D planning or modulated intensity, dosimetric and imaging controls whereas anesthesia was used in infants. RESULTS: forty seven patients survived (47.9 %) with a survival rate of 5 years (50.2 %) and a median of 5.34 years. CONCLUSIONs: radiation therapy proves to be an effective therapeutic tool for the treatment of central nervous tumors in children and adolescents.

Radioterapia em paciente com neoplasia pulmonar e marcapasso ipsilateral / Radiotherapy in a patient with pulmonary neoplasia and ipsilateral pacemaker

Durante anos, o tratamento com radioterapia de portadores de dispositivos eletrônicos implantáveisfoi considerado perigoso. Se a zona a ser irradiada envolvesse o lado em que o dispositivo estivesse localizado, aestratégia envolvia inclusive mudanças no local do implante. Passaram-se os anos e tanto os dispositivos como aradioterapia evoluíram, e o que antes era regra para a segurança do binômio marcapasso-radioterapia hoje pode serexceção. Relatamos o caso de um paciente portador de neoplasia maligna de lobo superior de pulmão direito, emposição ipsilateral ao marcapasso implantado previamente...

For years treatment with radiotherapy in patients with implantable electronic devices was considered dangerous. If the area to be irradiated involved the side where the device was located, the strategy involved including changes at the implant site. The years have gone by, the devices have evolved, radiotherapy has evolved,and what used to be the safety rule for the pacemaker-radiotherapy binomial may be the exception today. We report the case of a patient with malignant neoplasia of the upper lobe of the right lung, ipsilateral to a previously implanted pacemaker...

Plasmocitoma de la mama / Breast plasmocytoma

El plasmocitoma de la mama es muy infrecuente y en la mayoría de los casos aparece asociado a mieloma múltiple. Se describe una paciente de 42 años de edad con diagnóstico conocido de plasmocitoma solitario del cuello asociado a mieloma múltiple, que 11 meses después de alcanzada la remisión se presenta con una tumoración en la mama derecha sin manifestaciones sistémicas de mieloma. El estudio histológico e inmunohistoquímico del tumor confirmaron el diagnóstico de plasmocitoma. El diagnóstico diferencial en ocasiones es difícil y debe hacerse con tumores primarios y secundarios de la mama. El tratamiento de elección es la radioterapia local siempre que no existan manifestaciones sistémicas de la enfermedad subyacente(AU)

Breast plasmocytoma is infrequent and in most of the cases is associated to multiple myeloma. We describe a 42 year old woman with a diagnosis of solitary plasmocytoma of the neck associated to multiple myeloma that went into remission and eleven months later she presented a right breast lump which was confirmed by core biopsy and immunohistochemical study to be a plasmocytoma. Sometimes differential diagnosis is difficult and should be performed in primary and secondary breast tumours. The election treatment is radiotherapy if there are not manifestations of a subyacent sistemic disease(AU)

Detecção dos herpesvirus humanos na mucosa oral de pacientes irradiados para tratamento de carcinoma epidermoide em região de cabeça e pescoço / Detection of human herpesvirus in oral mucosa of patients undergoing radiotherapic treatment for head and neck squamous cell carcinoma

A radioterapia para tratamento das neoplasias malignas em região de cabeça e pescoço é acompanhada de diversas complicações, decorrentes do comprometimento dos tecidos radiossensíveis localizados próximos ao tumor. Entre essas complicações a mucosite é a que merece maior destaque. A mucosite é uma reação tóxica inflamatória da mucosa oral causada pelo tratamento citorredutivo induzido pela radioterapia (RT) ou pela quimioterapia (QT). Ela manifesta-se com sinais de edema, eritema, úlcera e formação pseudomembrana, resultando em sintomas de ardência, que pode progredir para dor intensa e consequente prejuízo na alimentação e comunicação verbal. Infecções bacterianas, fúngicas ou virais podem acometer a mucosa bucal irradiada e exacerbar a manifestação da mucosite oral por meio da ativação de fatores de transcrição da resposta inflamatória. Existem poucos dados na literatura sobre a participação dos herpesvirus humanos na mucosite oral induzida pela radioterapia. A proposta desse trabalho foi avaliar a excreção oral dos herpesvirus humanos (HSV-1, HSV-2, EBV, CMV, VZV, HHV6, HHV7 e HHV8) e sua possível associação com o desenvolvimento e agravamento da mucosite oral, em pacientes diagnosticados com carcinoma epidermoide (CEC) de boca e orofaringe, submetidos à radioterapia associado à quimioterapia. Nesse estudo foram analisadas 158 amostras de lavado bucal, de 20 pacientes, submetidos à radioterapia para CEC em região de cabeça e pescoço, coletadas semanalmente, durante todo o tratamento. Foi realizada a extração do DNA dessas amostras e em seguida sua amplificação através da PCR utilizando dois conjuntos de primers: HSVP1/P2 para os subtipos HSV-1, HSV-2, EBV, CMV e HHV-8 e o VZVP1/P2 para os subtipos VZV, HHV-6 e HHV-7

As amostras positivas foram submetidas à digestão enzimática com enzimas de restrição BamHI e BstUI para determinação específica de cada um dos oito herpesvirus. Foi também avaliada clinicamente, a mucosite oral, em cada uma das coletas, seguindo os critérios da OMS e NCIC. As análises da amostra mostraram a excreção do EBV, HHV-6 e HHV-7, em todas as semanas de tratamento radioterápico, enquanto que a excreção do HSV1 não pode ser observada no momento da triagem. Considerando-se todos os períodos em conjunto (Triagem, semanas de radioterapia e Controle), a maior frequência foi de pacientes que excretaram EBV (55,0%), seguida daqueles que excretaram HHV-7 (20,5%). A frequência de excreção de EBV foi significativamente maior do que a dos demais vírus (Teste ?2, p<0.001 para todos os cruzamentos). A frequência de excreção de HHV-7 foi significativamente maior do que a de HSV-1 (5,9%) e HHV-6 (5,5%) (Teste ?2, p=0.001 para ambos os cruzamentos). Não houve diferenças estatísticas significantes entre as frequências de HSV-1 e HHV-6. Como conclusão, verificou-se uma correlação positiva entre a excreção oral do EBV e a presença de mucosite induzida pela associação de radioterapia e quimioterapia com graus >=2, sobretudo se considerarmos as três últimas semanas de radioterapia, período este em que a severidade da mucosite foi estatisticamente maior. Esses achados nos possibilitam inferir que o ambiente inflamatório local de mucosites com grau >=2 seja mais favorável para excreção oral do EBV.

The radiotherapy (RT) treatment for head and neck tumors is accompanied by various complications resulting from the damage of the radiosensitive tissues located close to the tumor. Among these complications, mucositis is the one that deserves a special attention. Mucositis is an inflammatory toxic reaction of the oral mucosa caused by cytoreductive treatment induced by radiotherapy (RT) or chemotherapy (QT). The clinical manifestations of mucositis are: edema, erythema, ulcers and pseudo membrane formation, resulting in symptoms of burning, which may progress to severe pain and consequent loss in deglutition and verbal communication. The development of bacterial, fungal or viral infections, may affect the oral mucosa that has been irradiated, exacerbating the manifestation of oral mucositis through the activation of transcription factors of the inflammatory response. There are few data in the literature on the participation of human herpesvirus in oral mucositis caused by radiotherapy treatment. The aim of this study is to evaluate the oral excretion of human herpesvirus (HSV-1, HSV-2, EBV, CMV, VZV, HHV6, HHV7 and HHV-8) and its possible association with the development and aggravation of oral mucositis, in patients diagnosed with squamous cell carcinoma (CEC) of oral cavity and oropharynx, undergoing radiotherapy treatment associated with chemotherapy. On our study, we analyzed 158 oral rinsing samples, collected weekly, from 20 patients during the whole radiotherapy treatment for squamous cell carcinoma in head and neck. From these samples, we extracted the DNA and afterwards we amplified them with PCR using two sets of primers: HSVP1/P2 for the subtypes HSV-1, HSV-2, EBV, CMV, and HHV-8 and VZVP1/P2 for the subtypes VZV, HHV 6, and HHV-7.

The positive samples were subjected to enzymatic digestion with BamHI and BstUI restriction enzymes for specific determination of each one, of the eight's herpesvirus. It has also been clinically evaluated in each time, the oral mucositis, following the WHO and NCIC criteria. The analysis of the sample showed the excretion of EBV, HHV-6 and HHV-7, in all the weeks of radiotherapy, whereas the excretion of HSV-1 could not be observed during screening. Considering all periods together (Screening, weeks of radiotherapy and Follow up), the highest frequency was of patients with EBV excretion (55.0%), followed by those with HHV-7 excretion (20.5%).

Surgical treatment of complications resulting from adjuvant radiotherapy: a case report / Tratamento cirúrgico das complicações resultantes da radioterapia adjuvante: relato de caso

Introduction: Breast cancer is the leading cause of death among malignancies affecting women. Treatment options range from surgical treatment, radiotherapy, chemotherapy and hormone therapy. The immediate breast reconstruction helps to benefit the psychosocial aspects of patients, however, depend on the technique used a number of complications can appear, especially after adjuvant radiotherapy. Case report: We report a case of a 65-year-old woman, underwent quadrantectomy and radiotherapy in 1988. In 2010, the patient presented an injury on the scar and she was referred to mastectomy with reconstruction of retail large dorsal and adjuvant radiotherapy. Upon examination, we observed flap necrosis with infection on the axillary region, lymphedema, radiodermatitis, fibroses and joint limitation. In 2014, the patient sought our service to perform a new restorative approach. A bipedicled transverse abdominal flap was decided to be adequate to her case. After surgery, the patient reported mild pain in the upper pole that managed with debridement and dressing. Seven months after surgery there was a complete healing of the flap and patient was satisfied with the surgery. Conclusion: The knowledge of surgical techniques associated with the correct scaling of steps are essential for surgical success and management of complications that may appear in breast reconstruction of patients undergoing radiotherapy.

Introdução: O câncer de mama é a principal causa de morte entre as mulheres por doenças malignas. As opções de tratamento variam entre a abordagem cirúrgica, radioterápica, quimioterápica e hormonal. A reconstrução mamária imediata atua em aspectos psicossociais das pacientes, contudo, a depender da técnica realizada, diversas complicações podem surgir, principalmente pós-radioterapia adjuvante. Relato do caso: Paciente sexo feminino, 65 anos, submetida à quadrantectomia e radioterapia em 1988. Evoluiu com aparecimento de ferimento em local de cicatriz em 2010, sendo submetida à mastectomia com reconstrução com retalho grande dorsal imediata e radioterapia adjuvante. Apresentou necrose do retalho, com infecção em região axilar, linfedema, radiodermite, retração cicatricial intensa e limitação articular. Em 2014, procurou nosso serviço para nova abordagem reparadora. Indicado retalho transverso do abdome bipediculado. No seguimento pós-operatório houve pequeno sofrimento em polo superior manejado com desbridamentos e curativos. Após sete meses de pós-operatório, houve cicatrização completa do retalho e satisfação da paciente com procedimento cirúrgico. Conclusão: O conhecimento das técnicas cirúrgicas, associado ao correto escalonamento, é fundamental para um bom sucesso cirúrgico e manejo das complicações que venham a acontecer nas reconstruções mamárias em pacientes submetidas à radioterapia.

Re-Irradiation of Hepatocellular Carcinoma: Clinical Applicability of Deformable Image Registration

PURPOSE: This study aimed to evaluate whether the deformable image registration (DIR) method is clinically applicable to the safe delivery of re-irradiation in hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Between August 2010 and March 2012, 12 eligible HCC patients received re-irradiation using helical tomotherapy. The median total prescribed radiation doses at first irradiation and re-irradiation were 50 Gy (range, 36-60 Gy) and 50 Gy (range, 36-58.42 Gy), respectively. Most re-irradiation therapies (11 of 12) were administered to previously irradiated or marginal areas. Dose summation results were reproduced using DIR by rigid and deformable registration methods, and doses of organs-at-risk (OARs) were evaluated. Treatment outcomes were also assessed. RESULTS: Thirty-six dose summation indices were obtained for three OARs (bowel, duodenum, and stomach doses in each patient). There was no statistical difference between the two different types of DIR methods (rigid and deformable) in terms of calculated summation operatorD (0.1 cc, 1 cc, 2 cc, and max) in each OAR. The median total mean remaining liver doses (M(RLD)) in rigid- and deformable-type registration were not statistically different for all cohorts (p=0.248), although a large difference in M(RLD) was observed when there was a significant difference in spatial liver volume change between radiation intervals. One duodenal ulcer perforation developed 20 months after re-irradiation. CONCLUSION: Although current dose summation algorithms and uncertainties do not warrant accurate dosimetric results, OARs-based DIR dose summation can be usefully utilized in the re-irradiation of HCC. Appropriate cohort selection, watchful interpretation, and selective use of DIR methods are crucial to enhance the radio-therapeutic ratio.